Purpose

To investigate the efficacy and safety of plasma rich in growth factors (PRGF) eyedrops in the management of patients with ocular surface diseases in North America.

Methods

Multicenter interventional case series of patients using PRGF eyedrops for the first time. A cohort of patients was analyzed for corneal staining score at initial visit and at 3 months of therapy with PRGF. Another cohort responded to a 10-item questionnaire that evaluated patients' satisfaction and safety, which included the symptom assessment questionnaire in dry eye (SANDE) score, after 6 months of PRGF treatment.

Results

A total of 153 patients were analyzed. Of these, 102 were reviewed for corneal epitheliopathy and 99 patients responded to the questionnaire. The mean (±SD) age of the population was 63.7 ± 17 years and 72.5% were female. The clinical indications for PRGF usage were dry eye (60%), neurotrophic keratopathy (15%), dormant corneal ulcers (12%), limbal stem cell deficiency (10%), and cicatrizing conjunctivitis (4%). At the final visit, 74.3% of patients showed an improvement of their corneal staining. Those who had punctate epithelial erosions or epithelial defects were reduced from 76.5% to 47% and 23.5% to 7.8% respectively (p < 0.0001). Symptoms, measured via SANDE score, significantly decreased from a median of 90 to 34.6 out of 100 points on follow-up (p < 0.0001). Only one patient (0.98%) complained of ocular burning sensation as a side effect.

Conclusions

This multicentric study demonstrates the safety and efficacy of the use of PRGF for treating signs and symptoms in patients with significant ocular surface diseases.

中文翻译：

---

使用富含生长因子的血浆 (PRGF) 治疗北美眼表疾病患者的多中心报告

目的

研究富含生长因子（PRGF）的血浆滴眼液在北美治疗眼表疾病患者中的疗效和安全性。

方法

首次使用 PRGF 眼药水的多中心介入病例系列研究。在初次就诊和使用 PRGF 治疗 3 个月时分析一组患者的角膜染色评分。在 PRGF 治疗 6 个月后，另一个队列对评估患者满意度和安全性的 10 项问卷做出了回应，其中包括干眼症 (SANDE) 评分的症状评估问卷。

结果

共分析了 153 名患者。其中，102 名患者接受了角膜上皮病变检查，99 名患者对问卷做出了回应。人群的平均 (±SD) 年龄为 63.7 ± 17 岁，其中 72.5% 为女性。使用 PRGF 的临床适应症是干眼症 (60%)、神经营养性角膜病 (15%)、休眠角膜溃疡 (12%)、角膜缘干细胞缺乏症 (10%) 和瘢痕性结膜炎 (4%)。在最后一次就诊时，74.3% 的患者的角膜染色有所改善。那些有点状上皮糜烂或上皮缺损的人分别从 76.5% 减少到 47% 和 23.5% 到 7.8% (p < 0.0001)。通过 SANDE 评分测量的症状在随访中从 100 分中的 90 分显着下降到 34.6 分（p < 0.0001）。只有一名患者（0.

结论

这项多中心研究证明了使用 PRGF 治疗患有严重眼表疾病的患者的体征和症状的安全性和有效性。